EFG vs IVIG in TAMG

This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor (AChR) antibody-positive thymoma patients with myasthenia gravis in order to provide reliable evidence for clinical decision-making.

NCT Number	NCT07231523
Lead Sponsor	Shanghai Zhongshan Hospital Collaborators: The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tang-Du Hospital, West China Hospital, Second Affiliated Hospital of Soochow University, Huashan Hospital, The Affiliated Brain Hospital of Nanjing Medical University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Wuhan TongJi Hospital
Conditions	Efgartigimod, Intravenous Immunoglobulin, Myasthenia Gravis Associated With Thymoma
Enrollment	64 participants
Start Date	2025-12-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-17